Page 3 - Dr Reddys Laboratories Ltd News

Stocks to Watch today: RIL, Dr Reddy's Labs, Coforge, Hudco, Container Corp

Stocks to Watch Today, Monday, October 27, 2025: Reliance Industries, Container Corporation of India, PTC Industries, Mazagon Dock Shipbuilders, and Indian Oil are among the top stocks to watch today

Dr Reddy's Q2FY26 results: Profit up 14% at ₹1,437.2 cr, revenue jumps 10%

Dr Reddy's Ebitda for the quarter stood at ₹2,351.1 crore, up 3 per cent Y-o-Y and sequentially, with an Ebitda margin of 26.7 per cent

Q2 results today: Dr Reddy's Labs, ITC Hotels, NACL Industries on Oct 24

Aditya Birla Sun Life AMC, SBI Life Insurance Company, SBI Cards and Payment Services, India Radiators, and Sigachi Industries will also release their September quarter earnings reports today

Dr Reddy's Q2 preview: Profit may moderate as US sales dip; check estimates

Dr Reddy's net profit is expected to come at ₹1,479 crore, marking a moderate 5.5 per cent Y-o-Y increase, on average, as against ₹1,401 crore in the year-ago period

USFDA says 'voluntary action' required at Dr Reddy's Srikakulam unit

Drugmaker Dr Reddy's Laboratories Ltd on Tuesday said it has received establishment inspection report from the US health regulator for its formulations manufacturing facility at Srikakulam in Andhra Pradesh, classifying the facility as voluntary action indicated. The US Food & Drug Administration (USFDA) had conducted a GMP and a Pre-Approval Inspection (PAI) conducted by at the company's formulations manufacturing facility FTO 11 in Srikakulam, Andhra Pradesh, India, intimated to the exchanges on July 18, 2025, Dr Reddy's Laboratories Ltd said in a regulatory filing. "We wish to inform you that the company has received the Establishment Inspection Report (EIR) on October 20, 2025. The USFDA has classified the inspection outcome as 'Voluntary Action Indicated (VAI)'," it said, adding the inspection is officially closed. Under voluntary action indicated (VAI), while objectionable conditions were found and documented during an inspection, the agency is not prepared to take or ...

Lupin, Granules: Which pharma stocks to buy, sell amid US tariff flip-flop?

Technical charts show that select pharma stocks are trading with a negative bias and can tumble up to 19% from here. Granules India, however, looks strong on chart and can rally up to 19%.

Tariff relief buzz lifts Nifty Pharma Index; Lupin, Aurobindo lead gains

Pharma stocks were rising in trade today as export concerns eased on US tariff report. Check out the top stocks that may benefit from US tariff relief